| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9895447 | TEVA | Drug-containing PLA implants and methods of use thereof |
Jan, 2025
(8 months from now) | |
| US9439905 | TEVA | Risperidone-containing implants and methods of use thereof |
Jan, 2025
(8 months from now) | |
| US10736965 | TEVA | Risperidone biodegradable implant |
Jan, 2025
(8 months from now) | |
| US9717799 | TEVA | Drug-containing implants and methods of use thereof |
Jan, 2025
(8 months from now) | |
| US9925268 | TEVA | Drug-containing implants and methods of use thereof |
Jan, 2025
(8 months from now) | |
| US8802127 | TEVA | Risperidone-containing PLA:PGA implants and methods of use thereof |
Jan, 2025
(8 months from now) | |
| US8221778 | TEVA | Drug-containing implants and methods of use thereof |
Nov, 2027
(3 years from now) | |
| US8741327 | TEVA | Method of maintaining therapeutic risperidone levels in a PLA:PLGA implant |
Nov, 2027
(3 years from now) | |
| US9023897 | TEVA | Biodegradable drug delivery compositions |
Apr, 2033
(8 years from now) | |
Uzedy is owned by Teva.
Uzedy contains Risperidone.
Uzedy has a total of 9 drug patents out of which 0 drug patents have expired.
Uzedy was authorised for market use on 28 April, 2023.
Uzedy is available in suspension, extended release;subcutaneous dosage forms.
Uzedy can be used as treatment of schizophrenia.
The generics of Uzedy are possible to be released after 05 April, 2033.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Apr 28, 2026 |
Drugs and Companies using RISPERIDONE ingredient
Market Authorisation Date: 28 April, 2023
Treatment: Treatment of schizophrenia
Dosage: SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS
More Information on Dosage
UZEDY family patents
